[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-ckd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-ckd":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,68,94,126,160,186,210,232,258,287,315,337],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100651604","do-endocrine-disruptors-accumulate-in-children-undergoing-paediatric-dialysis-100651604",false,"NCT07763483","Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?","PedDIA-TOX","Inclusion Criteria:\n\n* Children aged 0 to 17 years (inclusive), followed in the Paediatric Nephrology Department of the Femme-Mère-Enfant Hospital, Hospices Civils de Lyon.\n* No objection from the parents or legal guardian(s).\n* Assent of the minor participant, when appropriate according to age and level of understanding\n* For group 1: Children with non-dialysis chronic kidney disease (CKD) stages 1-2, weighing at least 5 kg.\n* For group 2: Children with non-dialysis chronic kidney disease (CKD) stages 4-5, weighing at least 5 kg.\n* For group 3: Children receiving peritoneal dialysis, weighing at least 5 kg.\n* For group 4: Children receiving paediatric haemodialysis with pre-dilution hemodiafiltration, weighing at least 12 kg.\n* For group 5: Children receiving paediatric haemodialysis with post-dilution hemodiafiltration, weighing at least 12 kg.\n\nExclusion Criteria:\n\n* Participation in another interventional research study with an exclusion period still ongoing on the day of inclusion and deemed by the investigator to potentially interfere with the present study.\n* Individuals deprived of liberty by a judicial or administrative decision.","ALL","2 Years","17 Years",{"count":20,"type":21},15,"ESTIMATED","OBSERVATIONAL","The impact of the environment on health is becoming an increasingly important issue in public health policies. Endocrine disruptors (EDs) are substances or mixtures of substances found in many everyday products that interact with the body's endocrine functions. Although their mechanisms of action are not yet fully understood, mechanisms involving endocrine mimicry, antagonism, and epigenetic effects have been described.\n\nThe effects of the main endocrine disruptors on bone health remain poorly understood. Per- and polyfluoroalkyl substances (PFAS) constitute a large family of synthetic organic compounds used for their non-stick and heat-resistant properties. Perfluorooctanoic acid (PFOA) is a specific PFAS compound used in packaging materials and plastics. One of the known effects of PFAS is their interference with vitamin D through competition at its receptor, thereby reducing bone formation. In addition, PFAS decrease the proliferation of bone cells and reduce extracellular matrix synthesis.\n\nFrom foetal development through adolescence, early life represents a critical period for bone formation. If environmental chemicals can interfere with this process in the general paediatric population, the accumulation of endocrine disruptors may also exert an additional deleterious effect in the context of chronic kidney disease-mineral and bone disorder (CKD-MBD). Indeed, patients with chronic kidney disease (CKD) have a higher incidence of fractures and present mineral, skeletal, and cardiovascular abnormalities whose pathophysiology is extremely complex. The potential impact of endocrine disruptors on the pathophysiology of CKD-MBD in children has never been evaluated, despite the fact that during dialysis sessions, blood repeatedly circulates through a circuit composed mainly of plastics and exposed to elevated temperatures.\n\nIn adult dialysis populations, PFAS exposure has been investigated, but the results are contradictory. In 2018, Liu et al. found no evidence of PFAS removal by haemodialysis. Conversely, studies by Liu et al. (2018) and Huang et al. (2023) demonstrated a significant reduction in PFAS concentrations in patients following haemodialysis sessions and compared with patients with chronic kidney disease not receiving dialysis. Both research groups suggested that PFAS levels in dialysis patients are significantly influenced by the composition and properties of the dialysis membranes used.\n\nHowever, these studies were conducted exclusively in adults, who, by definition, do not have a growing skeleton, and were restricted to PFAS measurements. This is particularly relevant given that: (1) dialysis techniques are rapidly evolving, with hemodiafiltration increasingly replacing conventional haemodialysis and with different membrane types used in paediatric practice; and (2) children undergoing dialysis often require more frequent treatment sessions than adults. For example, according to the French national survey conducted on January 28, 2026, in preparation for discussions on a new dialysis reimbursement model, 25% of the 93 children receiving chronic haemodialysis underwent treatment more than three times per week. Furthermore, none of these studies assessed the impact of peritoneal dialysis, a modality that is relatively uncommon in adults but widely used in paediatrics, particularly among very young children.\n\nThese considerations have prompted us to evaluate PFAS serum concentrations in children with: (1) chronic kidney disease, (2) peritoneal dialysis, and (3) haemodialysis. This study is designed as a pilot project that may support the development of a larger-scale investigation depending on the results obtained.",[25],"Chronic Kidney Disease (CKD)",[27,28,29],"Endocrine disruptors","Paediatric dialysis","Chronic kidney disease","NOT_YET_RECRUITING","2026-08-13",{"date":33,"type":34},"2026-08-17","ACTUAL",{"date":36,"type":21},"2026-10-10",{"date":38,"type":21},"2028-04-10",{"name":40,"class":41},"Hospices Civils de Lyon","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100650295","assessment-of-dietary-balance-in-home-dwelling-patients-with-stage-4-and-5-chronic-kidney-disease-using-uriki-iki-a-connected-urine-test-strip-and-in-vitro-diagnostic-medical-device-100650295","NCT07746037","Assessment of Dietary Balance in Home-Dwelling Patients With Stage 4 and 5 Chronic Kidney Disease Using URIKI (IKI), a Connected Urine Test Strip and In Vitro Diagnostic Medical Device","URIKI-MRC","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Chronic kidney disease (CKD) stage 4 or 5 with estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m².\n* Followed in a nephrology department within a structured care pathway that includes nutritional assessment.\n* Clinical indication or need for nutritional assessment as part of routine care.\n* Willing and able to use the URIKI device for nutritional assessment.\n* Able to understand French or English, or assisted by a caregiver capable of supporting device use and understanding study procedures.\n* Agreement to the use of the device and to the collection and transmission of study-related data.\n* Affiliation with a social security system or beneficiary of such coverage.\n* Access to a compatible smartphone, a smartphone provided by IKI, or assistance from a caregiver for use of the mobile application\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Severe cognitive impairment preventing understanding of study procedures or use of the application without caregiver assistance.\n* Major motor or sensory impairments (e.g., blindness, hemiplegia) preventing use of the device without caregiver assistance.\n* Inability to understand French or English without support from a caregiver or third party.\n* Refusal of the loaned smartphone or persistent inability to use the provided equipment despite support.\n* Refusal to participate in the study or withdrawal after receiving study information.\n* Concurrent participation in another interventional clinical study deemed incompatible with this study, or an ongoing exclusion period related to another study.\n* Individuals under legal protection (guardianship or curatorship), unless participation is authorized by the legal representative and ethics committee","18 Years",{"count":52,"type":21},450,"INTERVENTIONAL",[55],"NA","The goal of this clinical trial is to evaluate whether the integration of URIKI, a connected urine test strip and in vitro diagnostic medical device, can improve the nutritional management of patients with stage 4 or 5 chronic kidney disease (CKD) living at home. The primary purpose is to assess whether URIKI can support dietary monitoring and optimize dietitians' workload through remote collection of urinary and nutrition-related data.\n\nThe main question it aims to answer is:\n\nDoes the integration of URIKI improve the efficiency of dietitians' work in the nutritional follow-up of patients with stage 4 or 5 chronic kidney disease?\n\nParticipants will:\n\nReceive a URIKI kit at home, including a portable reader, urine test strips, and access to the My URIKI mobile application.\n\nPerform one urine measurement per day at home for 10 consecutive days using the URIKI device.\n\nEnter nutrition- and health-related information into the application, including meal photographs or descriptions, hydration information, and responses to brief questionnaires.\n\nReceive remote support for installation and use of the device if needed. Have their urinary measurements reviewed by authorized healthcare professionals.\n\nReceive a personalized dietary assessment and nutritional feedback from the hospital medical team and\u002For IKI dietitians through the My URIKI application.\n\nComplete patient experience questionnaires at study entry and at the end of participation.\n\nThe expected duration of participation is up to 30 days. Approximately 450 patients with stage 4 or 5 chronic kidney disease will be enrolled in nephrology centers across France.",[25],"2026-08-03",{"date":60,"type":34},"2026-08-04",{"date":62,"type":21},"2026-10",{"date":64,"type":21},"2027-11",{"name":66,"class":41},"Assistance Publique - Hôpitaux de Paris",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100447434","an-observational-extension-study-for-adult-patients-treated-in-study-r5459-rt-1944-who-receive-a-kidney-transplant-100447434","NCT05106387","An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant","A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant","Inclusion Criteria:\n\n1. Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \\[NCT05092347\\].\n2. Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944\n3. Willing and able to comply with clinic visits and study-related procedures\n4. Provide informed consent signed by study patient or legally acceptable representative\n\nExclusion Criteria:\n\n1.There are no exclusion criteria for this study.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply","70 Years",{"count":77,"type":21},20,"The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347).\n\nNo study drug will be given during this study.",[25],[81],"Kidney Transplant","RECRUITING","2026-07-17",{"date":85,"type":34},"2026-07-20",{"date":87,"type":34},"2023-10-19",{"date":89,"type":21},"2028-02-23",{"name":91,"class":92},"Regeneron Pharmaceuticals","INDUSTRY",9,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":53,"phases":104,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":42},"100645741","remote-vs-in-person-prehabilitation-for-kidney-transplant-candidates-100645741","NCT07701382","Remote vs In-Person Prehabilitation for Kidney Transplant Candidates","Implementation of a Multimodal Prehabilitation Program for Patients With Advanced Chronic Kidney Disease Awaiting Deceased-Donor Kidney Transplantation: A Comparison of In-Person and Remote Delivery Models","KIDFIT","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients with advanced chronic kidney disease on the waiting list for deceased-donor kidney transplantation.\n* Ability to perform moderate-intensity physical exercise.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Absolute contraindication to physical exercise.\n* Severe cognitive impairment limiting participation in the intervention or assessments.\n* Active infection at the time of enrollment.\n* Clinically unstable medical condition.\n* Physical or musculoskeletal limitations preventing participation in the exercise program.",{"count":103,"type":21},84,[55],"Patients with advanced chronic kidney disease awaiting deceased-donor kidney transplantation frequently experience progressive functional decline, frailty, reduced mobility, and poor quality of life while on the transplant waiting list. Although multimodal prehabilitation programs based on exercise, nutritional optimization, and psychological support have shown promising benefits in major surgery, their implementation in kidney transplant candidates remains limited due to barriers related to accessibility, fatigue, transportation, and treatment burden.\n\nThis randomized single-center clinical trial aims to evaluate the feasibility, adherence, and effectiveness of a multimodal prehabilitation program in patients awaiting deceased-donor kidney transplantation, comparing an in-person supervised model with a remote home-based model supported by a digital platform. The primary outcome will be the change in functional capacity measured by the 6-Minute Walk Test (6MWT). Secondary outcomes include physical activity level, frailty, nutritional status, kidney disease-specific quality of life (KDQOL-36), postoperative recovery quality (QoR-15), postoperative complications, and program adherence.\n\nThe study seeks to generate clinically applicable evidence regarding the implementation and scalability of remote prehabilitation strategies in patients with advanced chronic kidney disease, with the potential to improve accessibility, sustainability, and perioperative outcomes in kidney transplantation.",[25,81,107,108],"Frailty","Prehabilitation",[110,111,112,113,114,115,116],"advanced chronic kidney disease","kidney transplantation","prehabilitation","functional capacity","perioperative care","quality of life","multimodal prehabilitation","2026-07-08",{"date":119,"type":34},"2026-07-14",{"date":121,"type":21},"2026-07",{"date":123,"type":21},"2029-05",{"name":125,"class":41},"Hospital Clinic of Barcelona",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":53,"phases":135,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":42},"100636992","phase-1-adia-med-of-winter-park-llc-chronic-kidney-disease-research-study-100636992","NCT07572890","Adia Med of Winter Park LLC Chronic Kidney Disease Research Study","Inclusion Criteria:\n\n* Age 18-80 years\n* Confirmed CKD diagnosis (eGFR 15-89 mL\u002Fmin\u002F1.73 m²)\n* Willingness to consider experimental treatments and comply with study requirements\n* Ability to obtain required bloodwork\n* Ability to attend all scheduled visits\n* Able to meet study cost requirements ($15,000 study fee) as described in the informed consent\n\nExclusion Criteria:\n\n* Has\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Immunocompromised\n* Malignancy history\n* Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion\n* Current dialysis (hemodialysis or peritoneal dialysis) or planned initiation of dialysis during the study period\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days\n* Has had Kidney transplant\n* Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening","80 Years",{"count":134,"type":21},100,[136],"PHASE1","The goal of this clinical trial is to learn whether a new regenerative treatment called AdiaVita, made from umbilical cord blood-derived stem cells and exosomes combined with glutathione, is safe and can help improve kidney function in adults with chronic kidney disease (CKD). In this condition, the kidneys gradually lose their ability to filter blood as well as they should. The main questions it aims to answer are whether AdiaVita plus glutathione improves kidney function better than control treatments, as measured by blood tests for estimated glomerular filtration rate (eGFR) and creatinine levels, and whether the treatment is safe with acceptable side effects. Researchers will compare three groups. One group will receive AdiaVita plus glutathione. A second group will receive glutathione plus a placebo for AdiaVita. The third group will receive placebos for both treatments. A placebo looks like the real treatment but contains no active ingredients. This will help determine if the full treatment works better than the controls. Approximately 100 adults aged 18 to 80 with stage 2 to 4 chronic kidney disease may participate. Participants will be randomly assigned to one of the three treatment groups. They will receive monthly intravenous infusions at the clinic for the first three months and apply a skin spray twice daily at home during that period. The study lasts 12 months total for each participant, with regular visits for blood tests, physical exams, and safety monitoring. Certain participants in the control groups may switch to the active AdiaVita treatment after three months if they meet safety criteria. This is a single-blind study, meaning participants will not know which treatment they receive. Participant safety is closely monitored by the research team and an independent board throughout the study.",[139,140,141,25,142],"Chronic Kidney Disease","Kidney Disease","Kidney Disease, Chronic","CKD",[144,145,146,147,139,142,148,149,150],"allogeneic stem cells","antioxidant therapy","stem cell therapy","stem cells","Regenerative medicine","Glutathione","Glutathione therapy","2026-06-16",{"date":153,"type":34},"2026-06-17",{"date":155,"type":21},"2026-05-18",{"date":157,"type":21},"2029-01",{"name":159,"class":41},"Adia Med of Winter Park LLC",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":22,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":42},"100640922","coronary-artery-disease-screening-in-patients-with-chronic-kidney-disease-100640922","NCT07585695","Coronary Artery Disease Screening in Patients With Chronic Kidney Disease","Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease","EVACKD","Inclusion Criteria:\n\n* Male or female patients aged over 18 years\n* Affiliated with the French social security system\n* Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m², or GFR \\\u003C 45 mL\u002Fmin\u002F1.73 m² with albuminuria \\> 30 mg\u002Fg, or GFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² with albuminuria \\> 300 mg\u002Fg)\n* Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment\n* Having expressed no objection to participation in this study\n\nExclusion Criteria:\n\n* Legally protected adult (Article L1121-8 of the French Public Health Code)\n* Person deprived of liberty (Article L1121-8 of the French Public Health Code)\n* Pregnant woman\n* Patient who has undergone a normal coronary exploration within the past year",{"count":169,"type":21},283,"25 Months","Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.",[25,173],"Coronary Artery Disease (CAD)",[139,175,176],"Coronary Flow Reserve","coronary artery disease","2026-05-06",{"date":179,"type":34},"2026-05-14",{"date":181,"type":21},"2026-06-01",{"date":183,"type":21},"2028-01-31",{"name":185,"class":41},"University Hospital, Grenoble",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":194,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":53,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":67},"100562803","exercise-and-monitoring-with-post-hospitalization-muscle-atrophy-to-sustain-intrinsic-capacity-and-strength-100562803","NCT06607913","Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength","BCCMA: Recovery of Aged Muscle After Disuse Atrophy (REMEDY): Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength (EMPHASIS)","EMPHASIS","Inclusion Criteria:\n\n* Age \\> 55 years\n* Diagnosis of stage 3-4 CKD or an eGFR of \\\u003C45 mL\u002Fmin\u002F1.73m2\n\nExclusion Criteria:\n\n* Cardiovascular risk: Poorly controlled hypertension (\\>160\u002F100)\n\n  * Coronary event in past 6 months\n  * Class III or IV CHF\n  * symptomatic angina at rest or during exercise\n  * Syncope in past year, without known resolution of cause\n* COPD requiring home oxygen\n* Contraindications to resistance training, including history of intracranial or retinal bleeding; Diabetes with active proliferative retinopathy\n* History of significant spinal osteoarthritis or spinal stenosis\n* Dementia (on medical record review or mini-mental status exam score)","55 Years",{"count":196,"type":21},250,[55],"The aging Veteran population has more frequent inpatient hospitalization than non-Veterans. In addition, older Veterans have an inability to fully recover muscle mass and function after hospital-acquired weakness. The problem of hospital-acquired weakness is greatly increased in at-risk Veteran populations such as those with chronic kidney disease (CKD). The purpose of this collaborative study involving Denver and Baltimore VAMC sites is to improve health through the detection and rehabilitation management of hospital-acquired weakness in those with CKD. The study goals include identifying and monitoring the optimal muscle assessment sites in clinical settings, examining how muscle health impacts length of hospital stay and physical resilience, and determining how home-based and supervised exercise comparatively addresses post-hospitalization physical resilience using performance tests and Veteran feedback.",[25],"2026-03-31",{"date":202,"type":34},"2026-04-07",{"date":204,"type":34},"2025-04-11",{"date":206,"type":21},"2029-09-30",{"name":208,"class":209},"VA Office of Research and Development","FED",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":53,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":42},"100630897","multimedia-health-education-on-physical-fitness-and-physical-activity-for-patients-with-chronic-kidney-disease-100630897","NCT07493642","Multimedia Health Education on Physical Fitness and Physical Activity for Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Conscious adults aged 20 years or older who are literate and able to communicate in Mandarin or Taiwanese.\n* Diagnosed with chronic kidney disease (CKD) stage 1 to 3b according to the CKD-EPI formula and confirmed by a nephrologist.\n* Able to operate a mobile device (such as a smartphone, tablet, or computer) and have access to equipment capable of playing multimedia videos; family members or caregivers may assist if necessary.\n* Able to view and understand multimedia educational video content.\n\nExclusion Criteria:\n\n* Individuals with cognitive or psychiatric disorders that prevent understanding or adherence to the exercise program.\n* Individuals with gait instability or limb amputation who are unable to perform the exercise protocol.\n* Individuals with poorly controlled cardiovascular disease, such as heart failure, myocardial infarction, angina, arrhythmia, or those who have experienced chest pain during activity or rest within the past three months.\n* Individuals deemed unsuitable for exercise by their attending physician.\n* Individuals with poorly controlled diabetes (HbA1C \\> 9%) accompanied by retinopathy or foot ulcers.","20 Years",{"count":218,"type":21},60,[55],"This clinical trial aims to determine whether a multimedia educational intervention can effectively improve physical fitness and physical activity levels in patients with chronic kidney disease (CKD), while also evaluating its overall outcomes.\n\nThe study primarily seeks to answer the following questions:\n\n* Can multimedia education enhance CKD patients' cardiorespiratory endurance, muscle strength, flexibility, and physical activity levels?\n* Do patients receiving multimedia education demonstrate greater improvements in health behavior and fitness compared to those receiving standard education alone?\n\nResearchers will compare a multimedia educational video program with conventional patient education to assess whether the multimedia approach helps patients maintain regular exercise and improve physical performance.\n\nParticipants will:\n\n* Be randomly assigned to either the multimedia education group or the standard education group.\n* Take part in a 12-week intervention and assessment period.\n* Undergo pre- and post-intervention evaluations, including:\n* Six-minute walk test, grip strength and chair-stand test, flexibility test, and body composition analysis (BMI, waist-to-hip ratio, InBody).\n* Completion of a physical activity questionnaire (IPAQ-C). The findings will be used to evaluate the clinical value of multimedia education in CKD management and to support the development of effective patient exercise education programs.",[25,222],"CKD Stage 1-3","2026-03-23",{"date":225,"type":34},"2026-03-25",{"date":227,"type":34},"2025-11-17",{"date":229,"type":21},"2026-07-31",{"name":231,"class":41},"Fu Jen Catholic University Hospital",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":239,"sex":16,"minAge":50,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":42},"100531625","multifrequency-mre-in-evaluation-of-chronic-kidney-diseases-100531625","NCT06202235","Multifrequency MRE in Evaluation of Chronic Kidney Diseases","Multifrequency Renal MR Elastography in Evaluation of Chronic Kidney Diseases: Can Shear Stiffness Evaluate Renal Fibrosis in GFR-normal Patients?","Inclusion Criteria:\n\n(1) adults with CKD defined according to the 2024 KDIGO guidelines, with either elevated SCr or abnormal proteinuria ; and (2) renal MRI was performed within 7 days of the renal biopsy.\n\nExclusion criteria:\n\n(1) genitourinary malignancy, polycystic kidney disease, renal transplantation, or acute renal failure; (2) contraindications for MRI examination; (3) poor image quality; (4) kidney deformity or severe hydronephrosis on MRI; and (5) poorly defined corticomedullary demarcation.",true,"65 Years",{"count":242,"type":21},200,"Chronic Kidney Disease (CKD) is a major public health issue, leading to high mortality and the necessity for renal replacement therapy. Kidney fibrosis, resulting from chronic damage to kidney tissue, significantly determines CKD outcomes. Kidney biopsy, the gold standard for assessing fibrosis, is invasive and limited in its ability to reflect the heterogeneous nature of fibrosis. Consequently, there is growing interest in noninvasive methods, particularly Magnetic Resonance Elastography (MRE). MRE, which evaluates tissue stiffness, has shown potential for assessing kidney fibrosis. This study aims to use multifrequency MRE to assess renal fibrosis, focusing particularly on the early stages of CKD, to enhance understanding of its progression and relationship to clinical outcomes.",[25],[246,247,248],"chronic kidney disease","kidney fibrosis","MR elastography","2026-02-07",{"date":251,"type":34},"2026-02-10",{"date":253,"type":34},"2022-10-10",{"date":255,"type":21},"2027-06-08",{"name":257,"class":41},"Shengjing Hospital",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":265,"targetDuration":267,"studyType":22,"phases":4,"briefSummary":268,"conditions":269,"keywords":272,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":4},"100607784","the-cph-mbd-cohort-100607784","NCT07193056","The CPH-MBD Cohort","Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort","Inclusion Criteria:\n\n* Age ≥18 years\n* CKD stage 4-5nonD (eGFR ≤ 29 ml\u002Fmin) according to KDIGO (Kidney Disease Improving Global Outcome) definition\n\nExclusion Criteria:\n\n* None",{"count":266,"type":21},1000,"25 Years","Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).\n\nThe overall aim of the present project is to explore factors that may predict or associate with the development of bone and cardiovascular disease in patients with CKD and hopefully provide insight into underlying mechanisms and pathophysiological pathways for future treatment and prevention.\n\nIn a sub study investigators aim to explore the calcium and phosphate balance in patients with CKD and describe how these associate with each other as well as with kidney function (eGFR).",[270,25,271],"Chronic Kidney Disease Mineral and Bone Disorder","Bone Markers",[273,274,275,276,277],"bone markers","parathyroid hormone","fracture risk","bone turnover","dietary assessment","2025-12-24",{"date":280,"type":34},"2025-12-31",{"date":282,"type":21},"2025-12",{"date":284,"type":21},"2055-01",{"name":286,"class":41},"Herlev Hospital",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":239,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":294,"targetDuration":296,"studyType":22,"phases":4,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":42},"100601160","non-interventional-pre-screening-protocol-aims-to-evaluate-participants-for-potential-trial-eligibility-in-future-clinical-trialsstudies-focusing-on-metabolic-and-psychiatric-health-100601160","NCT07106879","Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials\u002FStudies Focusing on Metabolic and Psychiatric Health.","Pre-screening Survey for Metabolic, Cardiovascular, Obesity, Mental Health, and Endocrine Trial Eligibility (DOVE-MET-COME-100)","Inclusion Criteria:\n\n* Any participant of age 18 years and over\n* Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Individuals having severe cognitive impairment or inability to provide informed consent\n* Individuals having acute psychiatric emergencies requiring immediate intervention\u002Fhospitalization\n* Individuals who are currently participating in another research study that conflicts with pre-screening data collection\n* Individuals having known history of drug\u002Falcohol misuse\n* Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.",{"count":295,"type":21},7000,"5 Years","DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.",[299,300,301,302,303,304,305,25],"Cardiovascular Diseases","Metabolic Syndrome","Obesity","Prediabetes","Mental Health Disorders","Endocrine Dysfunction","Type 2 Diabetes Mellitus (T2DM)","2025-08-11",{"date":308,"type":34},"2025-08-12",{"date":310,"type":34},"2025-07-30",{"date":312,"type":21},"2030-12-01",{"name":314,"class":41},"Clindove Research LLC",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":53,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":335,"locationsCount":4},"100596607","kermit-sweat-patch-for-early-kidney-disease-detection-100596607","NCT07047664","KERMIT: Sweat Patch for Early Kidney Disease Detection","Kidney Disease Sweat Sensor Patch for Early Diagnosis and Remote MonIToring","KERMIT","Inclusion Criteria:\n\nAdults aged ≥18 years with stable CKD, defined as:\n\n* eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m², or\n* eGFR ≥ 60 mL\u002Fmin\u002F1.73 m² with documented evidence of kidney damage (persistent albuminuria, structural abnormalities on imaging or histology, or genetic kidney disease).\n\nExclusion Criteria:\n\n* Any signs of dermal infections, open wounds, or skin irritation.\n* Significant variations in eGFR in the last two months, defined as any absolute change (either increase or decline) in eGFR of \\>10 mL\u002Fmin\u002F1.73m2 ;\n* Patients with a functioning kidney graft;\n* Patients receiving immunosuppression treatment;\n* Patients with kidney stones;\n* Patients with uncontrolled hypertension (a systolic blood pressure (SBP) \\>150 mmHg and\u002For diastolic blood pressure (DBP) \\>90 mmHg with measurements taken under standardized conditions (e.g after a 5-minute seated rest, using validated equipment);\n* Patients receiving drugs reported to affect serum levels of creatinine and cystatin-c without affecting kidney function (i.e. cimetidine, trimethoprim, and fibrates);\n* Known allergy to pilocarpine,\n* Glaucoma;\n* Patients with metal implants;\n* Pregnancy;\n* Active malignancy;\n* Low life expectancy (\\\u003C6 months) according to investigators judgement",{"count":324,"type":21},52,[55],"Chronic kidney disease (CKD) affects over 10% of the global population, leading to significant morbidity, mortality, and economic burden. Early detection is crucial for preventing disease progression and complications; however, awareness and diagnosis of CKD remain alarmingly low. Current methods rely on blood or urine analysis, which are invasive and require specialized facilities. The KERMIT patch aims to address this gap by providing a wearable lab-on-a-chip device capable of measuring key biomarkers from sweat non-invasively. This innovation has the potential to revolutionize CKD diagnosis, particularly in remote or underserved areas.\n\nThe KERMIT patch integrates functional printed biosensors, a high-frequency electrochemical microchip, and a sustainable microfluidic system. Sensors are fabricated using carbon inks and 2D materials, enabling immunodetection and non-enzymatic sensing of creatinine, urea, and cystatin C. Preliminary tests evaluated detection limits, skin compatibility, and carbon footprint.",[25],[142],"2025-06-23",{"date":331,"type":34},"2025-07-02",{"date":333,"type":21},"2025-07-01",{"date":121,"type":21},{"name":336,"class":41},"University of Ioannina",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":344,"targetDuration":346,"studyType":22,"phases":4,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":42},"100564931","chronic-kidney-disease-hyperkalemia-and-echocardiographic-changes-100564931","NCT06635590","Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes","The Impact of Hyperkalemia-Induced ECG and ECHO Findings on Early and Late Mortality in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n1. Patients over 18 years old\n2. Chronic kidney disease patients with eGFR \\< 60 mL\u002Fmin\u002F1.73 m²\n3. Patients with hyperkalemia detected in the emergency department\n4. Patients willing to participate in the study and who sign the consent form\n\nExclusion Criteria:\n\n1. Patients under 18 years old\n2. Patients who do not wish to participate in the study\n3. Patients without chronic kidney damage\n4. Patients without detected hyperkalemia\n5. Patients needing cardiopulmonary resuscitation due to hyperkalemia",{"count":345,"type":21},40,"30 Days","Patients with CKD ( eGFR \\< \\<60 mL\u002Fmin\u002F1,73 m2) presenting to emergency department with isolated hyperkalemia will be study population. Pre and post treatment ECG and echocardiographic findings will be recorded. Investigator will not intervene with the treatment decision of responsible physician and will not delay any intervetion or treatment for the sake of study.\n\nData will be compared in terms of ECHO and ECG findings depending on hyperkalemia level and response to treatment.",[25,349,350],"Hyperkalemia","Hemodialysis",[352,353,246,354],"echocardiography","ECG","hyperkalemia","2024-10-08",{"date":357,"type":34},"2024-10-10",{"date":359,"type":34},"2024-02-01",{"date":361,"type":21},"2025-02-01",{"name":363,"class":41},"Saglik Bilimleri Universitesi"]